✅ This trial is currently recruiting volunteers
If you think you might be eligible, speak to your GP or specialist about this trial before applying.
Status
Recruiting
Phase
PHASE1
Participants
ALL
Age Range
18 Years – 65 Years
About This Trial
The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.
Who Can Join?
Inclusion Criteria: – Each participant must meet all of the following inclusion criteria to be enrolled in the study: 1. Male and female patients 18 to 65 years old at screening 2. Must have a diagnosis of MS, and: * Patients with RRMS must be on DMT * Patients with progressive MS must not be on DMT 3. Participants with RRMS must be on stable DMT (i.e. must not have had a relapse within 1 month prior to the screening visit). Patients on tecfidera, cladribine, ocrelizumab, alemtuzumab, fingolimod or natalizumab must be enrolled with caution, at Chief Investigator's (CI) discretion because of the lymphopenia caused by these drugs and the risk of thrombocytopenia in 1-2 % of people after alemtuzumab 4. OCB positive CSF either from a previous CSF analysis or from the screening CSF analysis 5. Able and willing to give written informed consent and comply with protocol requirements…
⚠ Always speak to your doctor before applying to any clinical trial.